ELI LILLY & Co LLY

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Last close 1,273.46 2026-10-23
Market cap $1.20T 2026-06-30 share count
52-week range 809.63 - 1,321.21

Valuation FY2025 figures against the last close

P/S18.4x
P/E55.5x
P/FCF71.3x
EV/EBITDA—
Dividend yield0.4%
Diluted EPS22.95

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S.
  • Europe
  • Rest of world
  • Japan
  • China
Revenue by geography, 5 categories over 3 years. The same figures are in the table below. FY2025 U.S., FY2025: 43.5B (66.7%) 67% U.S. Europe, FY2025: 11.6B (17.7%) 18% Europe Rest of world, FY2025: 6.1B (9.3%) 9% Rest of world Japan, FY2025: 2.1B (3.3%) China, FY2025: 2B (3.0%) FY2024 U.S., FY2024: 30.4B (67.4%) 67% Europe, FY2024: 6.9B (15.4%) 15% Rest of world, FY2024: 4.3B (9.5%) 9% Japan, FY2024: 1.8B (4.0%) 4% China, FY2024: 1.7B (3.7%) 4% FY2023 U.S., FY2023: 21.8B (63.9%) 64% Europe, FY2023: 6.2B (18.1%) 18% Rest of world, FY2023: 2.9B (8.6%) 9% Japan, FY2023: 1.7B (4.9%) 5% China, FY2023: 1.5B (4.5%) 5%
Region FY2025FY2024FY2023
U.S. $43.48B $30.38B $21.79B
Europe $11.56B $6.92B $6.17B
Rest of world $6.06B $4.27B $2.95B
Japan $2.13B $1.81B $1.67B
China $1.95B $1.66B $1.54B

As the company reported it, from the “Revenue - Disaggregation of Revenue by Geographical Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $65.18B$45.04B$34.12B$28.54B$28.32B$24.54B$22.32B$21.49B$19.97B$18.31B
Cost of revenue $11.05B$8.42B$7.08B$6.63B$7.31B$5.48B$4.72B$4.68B$4.45B$4.16B
Gross profit $54.13B$36.62B$27.04B$21.91B$21.01B$19.06B$17.60B$16.81B$15.53B$14.15B
R&D ———$7.19B$6.93B$5.98B$5.59B$5.05B$5.10B$5.04B
SG&A $11.09B$8.59B$7.40B$6.44B$6.43B$6.12B$6.21B$5.98B$5.98B$5.84B
Interest expense $895.0M$781.0M$486.0M$331.6M$339.8M$359.6M$400.6M$242.5M$225.0M$185.2M
Pre-tax income $25.73B$12.68B$6.55B$6.81B$6.16B$7.23B$5.27B$3.68B$2.30B$3.28B
Income tax $5.09B$2.09B$1.31B$561.6M$573.8M$1.04B$628.0M$529.5M$2.39B$551.4M
Net income $20.64B$10.59B$5.24B$6.24B$5.58B$6.19B$8.32B$3.23B-$204.1M$2.74B
EPS, basic 23.0011.765.826.936.156.828.933.14-0.192.59
EPS, diluted 22.9511.715.806.906.126.798.893.13-0.192.58
Shares, diluted (wtd. avg.) 899.3M904.1M903.3M904.6M911.7M912.5M935.7M1.03B1.05B1.06B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $7.27B$3.27B$2.82B$2.07B$3.82B$3.66B$2.34B$7.32B$6.21B$4.58B
Short-term investments —$154.8M$109.1M$144.8M$90.1M$24.2M$101.0M$88.2M$1.50B$1.46B
Receivables $17.76B$11.01B$9.09B$6.90B$6.67B$5.88B$4.55B$4.59B$3.98B$4.03B
Inventory $13.74B$7.59B$5.77B$4.31B$3.89B$3.98B$3.19B$3.10B$3.40B$3.56B
Total current assets $55.63B$32.74B$25.73B$18.03B$18.45B$17.46B$13.71B$20.55B$19.20B$15.10B
Property, plant and equipment $24.68B$17.10B$12.91B$10.14B$8.99B$8.68B$7.87B$8.00B$7.89B$8.25B
Goodwill $5.90B$5.77B$4.94B$4.07B$3.89B$3.77B$3.68B$1.37B$1.38B$3.97B
Other intangibles $6.52B$6.17B$6.91B$7.21B$7.69B$7.45B$6.62B$1.07B$1.35B$4.36B
Total assets $112.48B$78.72B$64.01B$49.49B$48.81B$46.63B$39.29B$43.91B$44.98B$38.81B
Accounts payable $5.38B$3.23B$2.60B$1.93B$1.67B$1.61B$1.41B$1.21B$1.21B$1.35B
Short-term debt $1.64B$5.12B$6.90B$1.50B$1.54B$8.7M$1.50B$1.10B$3.71B$1.94B
Total current liabilities $35.23B$28.38B$27.29B$17.14B$15.05B$12.48B$11.78B$11.89B$14.54B$10.99B
Long-term debt $40.87B$28.53B$18.32B$14.74B$15.35B$16.59B$13.82B$9.20B$9.94B$8.37B
Retained earnings $24.47B$13.54B$10.31B$10.04B$8.96B$7.83B$4.92B$11.40B$13.89B$16.05B
Total equity $26.54B$14.27B$10.77B$10.65B$8.98B$5.64B$2.61B$9.83B$11.59B$14.01B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $16.81B$8.82B$4.24B$7.59B$7.37B$6.50B$4.84B$5.52B$5.62B$4.85B
Depreciation and amortisation $2.00B$1.77B$1.53B$1.52B$1.55B$1.32B$1.23B$1.61B$1.57B$1.50B
Stock-based compensation $626.0M$646.0M$629.0M$371.1M$342.8M$308.1M$312.4M$279.5M$281.3M$255.3M
Investing cash flow -$10.97B-$9.30B-$7.15B-$3.76B-$2.87B-$2.26B-$8.08B$1.91B-$3.78B-$3.14B
Financing cash flow -$2.21B$1.23B$3.50B-$5.41B-$4.13B-$3.14B-$2.32B-$5.90B$142.6M-$559.8M
Dividends paid $5.38B$4.68B$4.07B$3.54B$3.09B$2.69B$2.41B$2.31B$2.19B$2.16B
Buybacks $4.11B$2.50B$750.0M$1.50B$1.25B$500.0M$4.40B$4.15B$299.8M$600.1M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000059478-26-000013.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -20B 0 20B 40B 60B 80B Revenue, FY2016: 18.3B Gross profit, FY2016: 14.2B Net income, FY2016: 2.7B Revenue, FY2017: 20B Gross profit, FY2017: 15.5B Net income, FY2017: -204.1M Revenue, FY2018: 21.5B Gross profit, FY2018: 16.8B Net income, FY2018: 3.2B Revenue, FY2019: 22.3B Gross profit, FY2019: 17.6B Net income, FY2019: 8.3B Revenue, FY2020: 24.5B Gross profit, FY2020: 19.1B Net income, FY2020: 6.2B Revenue, FY2021: 28.3B Gross profit, FY2021: 21B Net income, FY2021: 5.6B Revenue, FY2022: 28.5B Gross profit, FY2022: 21.9B Net income, FY2022: 6.2B Revenue, FY2023: 34.1B Gross profit, FY2023: 27B Net income, FY2023: 5.2B Revenue, FY2024: 45B Gross profit, FY2024: 36.6B Net income, FY2024: 10.6B Revenue, FY2025: 65.2B Gross profit, FY2025: 54.1B Net income, FY2025: 20.6B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $18.31B $19.97B $21.49B $22.32B $24.54B $28.32B $28.54B $34.12B $45.04B $65.18B
Gross profit $14.15B $15.53B $16.81B $17.60B $19.06B $21.01B $21.91B $27.04B $36.62B $54.13B
Net income $2.74B -$204.1M $3.23B $8.32B $6.19B $5.58B $6.24B $5.24B $10.59B $20.64B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Other event Item 8.01
  • Results announced Item 2.02
  • Shareholder vote Item 5.07
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%
REGN REGENERON PHARMACEUTICALS, INC. $82.76B 19.4x 1.0%